Lipocine's postpartum depression drug fails primary endpoint in phase 3 trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Lipocine's postpartum depression drug fails primary endpoint in phase 3 trial
LIPOCINE (NASDAQ: LPCN) Delayed: 2.53 +0.24 (10.48%)
Previous Close $2.29    52 Week High $14.80 
Open $2.24    52 Week Low $2.51 
Day High $2.67    P/E N/A 
Day Low $2.24    EPS $-0.69 
Volume 207,822